Our Reports
Automotive Reports Electronics & Semiconductor Telecom & IT Technology & IT Consumer Goods Healthcare Food & Beverages Chemical
Our Links
About Us Contact Us Press Release News Our Blogs

Int'l : +1(646) 600-5072 | query@kbvresearch.com


The Global Sciatica Treatment Market is Predict to reach $810.4 Million by 2028, at a CAGR of 3.5%

Special Offering :

Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support

Sciatica Treatment Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Sciatica Treatment Market size is expected to reach $810.4 Million by 2028, rising at a market growth of 3.5% CAGR during the forecast period.

The Acute segment is showcasing a CAGR of 3.9% during (2022 - 2028). The symptoms of acute sciatica may continue for up to six weeks and include lower back pain with radiculopathy below the knee. The reasons driving the development of the acute sciatica category include a rising demand for over-the-counter analgesics for sciatica therapy and a rise in public awareness of sciatica treatment.

The Retail & Specialty Pharmacies segment acquired maximum revenue share in the Global Sciatica Treatment Market by Distribution Channel in 2021 thereby, achieving a market value of $373.8 Million by 2028. This is because it has extensive chains of distribution networks, creative marketing techniques, and offers patients superior financial & debt management. The main factor driving market expansion in this niche is the accessibility of drugs for sciatica, such as painkillers.

The Steroids segment has shown the growth rate of 4.4% during (2022 - 2028). Steroids may aid with sciatic pain relief by reducing inflammation. The medication is administered close to compressed spinal nerve roots during an epidural steroid injection. While there hasn't been much study on the efficacy of the therapy up to this point, many physicians still recommend oral steroids for sciatica.

The North America market dominated the Global Sciatica Treatment Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $298.2 Million by 2028. The Europe market is exhibiting a CAGR of 3.1% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 4.3% during (2022 - 2028).

Full Report: https://www.kbvresearch.com/sciatica-treatment-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sorrento Therapeutics, Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Novartis AG, and Cadila Healthcare Ltd. (Zydus Cadila)

Global Sciatica Treatment Market Segmentation

By Type

  • Chronic
  • Acute
  • Others

By Distribution Channel

  • Retail & Specialty Pharmacies
  • Hospital Pharmacies
  • Online Providers

By Drug Class

  • Non-Steroidal anti-inflammatory
  • Steroids
  • Antidepressants
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Abbott Laboratories
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Sorrento Therapeutics, Inc.
  • Alkem Laboratories Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Limited
  • Novartis AG
  • Cadila Healthcare Ltd. (Zydus Cadila)

Related Reports:



SUBSCRIPTION MODEL